Sign In
Buy BCDA
$0.82
+0.0531 (+6.89%)
At Close: Jul 31, 2026
SUNNYVALE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
Focus on Patients with Elevated Markers of Heart Stress and Inflammation Procedural enhancement using FDA Approved Morph DNA steerable guide for therapeutic delivery SUNNYVALE, Calif., Feb. 13, 2025 (
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have b
BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure
08:30am, Wednesday, 04'th Dec 2024
SUNNYVALE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
07:49pm, Wednesday, 13'th Nov 2024
BioCardia, Inc. (NASDAQ:BCDA ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chi
BioCardia Regains Full Compliance with Nasdaq Listing Requirements
08:30am, Wednesday, 18'th Sep 2024
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
04:05pm, Monday, 09'th Sep 2024
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
08:30am, Thursday, 29'th Aug 2024
SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
07:00am, Wednesday, 21'st Aug 2024
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript
07:53pm, Tuesday, 13'th Aug 2024
BioCardia, Inc. (NASDAQ:BCDA ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Miranda Peto - Investor Relations Peter Altman - President and CEO David McClung - Chief
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
04:30pm, Tuesday, 13'th Aug 2024
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
Bet on 5 Top-Ranked Stocks With Rising P/E
09:01am, Monday, 12'th Aug 2024
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include TAL Education Group (TAL), BioCardia (BCDA), Angi (ANGI), Xcel Energy (XEL) and SoFi Technologies
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
07:00am, Wednesday, 17'th Jul 2024
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise
BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.
BioCardia Announces Reverse Stock Split
05:00pm, Tuesday, 21'st May 2024
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, to
